Interview of EORTC members about COVID-19 impact on cancer clinical trials

The COVID-19 pandemic has affected cancer clinical trials in many ways, creating challenges and new opportunities.

Recruitment of many studies slowed down, patients did not dare to go to the hospital due to the fear of infection and mobility limitations as shortage of research staff.

During the pandemic, clinical investigators had to adapt quickly to continue the follow-up of their patients by setting remote monitoring, remote dispensation of medications for patients, telematics clinical visits, etc.

Our members share their stories on the impact of the pandemic and how they overcame the challenges, which resulted in being beneficial to patients.

Watch the interviews of our members:

Prof. Josep Tabernero, Vall d’Hebron University Hospital & Vall d’Hebron Institute of Oncology, Barcelona, Spain

Prof. Yolande Lievens, UZ Ghent, Belgium

Prof. Piotr Rutkowski, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

Prof. Kristin Bjordal, University of Oslo, Norway

Prof. Jean-Yves Blay, Centre Léon Bérard, Lyon, France